Cerus Corporation is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's primary products include the INTERCEPT Blood System for platelets and plasma, which are approved for use in the U.S., Europe, the Commonwealth of Independent States, the Middle East, and Latin America. In the U.S., the company also markets the INTERCEPT Blood System for Cryoprecipitation, used to produce INTERCEPT Fibrinogen Complex (IFC) for the treatment of bleeding associated with fibrinogen deficiency. The INTERCEPT Blood System for red blood cells is currently in late-stage clinical development, with a Phase 3 trial completed in the U.S. and regulatory applications under review in Europe. Cerus sells its products through a direct sales force and distributors to blood centers, hospitals, and manufacturing partners. The company was incorporated in 1991 and has a wholly-owned subsidiary, Cerus Europe B.V., formed in the Netherlands in 2006.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage cerus.com
Sector Healthcare IR page ir.cerus.com/home/default.aspx
Tags
blood safety, pathogen reduction, blood components, platelets, plasma, fibrinogen complex, transfusion medicine, clinical trials, INTERCEPT Blood System, INTERCEPT Blood System for Platelets, INTERCEPT Blood System for Plasma, INTERCEPT Blood System for Cryoprecipitation, INTERCEPT Blood System for Red Blood Cells, INTERCEPT Fibrinogen Complex, IFC, Cerus Europe B.V., INTERCEPT Illuminator
Press page —

Metrics

Valuation  
Market cap $ 480.651M
Market cap (USD) $ 480.651M
P/E -65.72
PEG —
P/BV 6.35
P/S 2.06
P/OCF 137.45
P/FCF 972.98
Dividend yield —
Turnover / mcap —
Returns  
ROE -26.0%
ROI -10.6%
ROIC -4.4%
Profit margin -6.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 130.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 233.798M 201.321M 186.797M 188.315M 159.518M 114.249M 93.774M 76.051M 51.326M 39.275M 34.223M 36.416M 39.657M 36.786M 33.044M 23.109M 17.982M 16.507M 11.044M 35.58M 24.371M 13.911M 9.665M 8.49M 4.535M 1.851M 2.408M 2.903M
Net profit -15.627M -20.918M -37.489M -42.779M -54.374M -59.857M -71.244M -57.564M -60.585M -62.906M -55.868M -38.755M -43.337M -15.917M -16.982M -16.911M -24.135M -29.181M -45.304M -4.779M 13.064M -31.153M -58.267M -57.192M -49.367M -36.033M -22.628M -29.558M
Free cash flow 1.108M 8.522M -47.765M -27.615M -34.832M -42.358M -74.773M -32.39M -52.588M -54.092M -51.851M -41.917M — -13.998M -15.79M -15.96M -14.855M -35.739M -38.102M -15.793M -15.803M -13.322M -58.912M -60.685M -45.236M -34.654M -34.007M -10.046M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 2.06 1.54 2.16 3.65 6.81 6.92 4.22 5.07 3.38 4.35 6.32 6.24 6.45 3.16 2.8 3.91 0.71 0.71 5.79 6.1 — — — — — — — —
Price performance 12m 0.34 -0.29 -0.41 -0.46 -0.02 0.64 -0.17 0.5 -0.22 -0.31 0.01 -0.03 1.04 0.13 -0.28 4.49 0 -0.88 -0.05 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 6.87M 12.4M 8.75M 16.9M 21.2M 25.1M 34.4M 35.5M 29.8M 30.4M
↳ YoY growth +18.5% +80.8% -29.5% +92.9% +25.4% +18.7% +37.0% +3.1% -16.1% +2.0%
↳ 5y CAGR +2.4% +22.8% +7.4% +25.2% +29.6% +29.6% +22.6% +32.3% +12.0% +7.5%
Lease liabilities (USD) — — — 20M 18.8M 18.2M 17.4M 16.2M 13.9M 13.1M
Cash and deposits (USD) 22.6M 13.7M 28.9M 35M 36.6M 48.8M 35.6M 11.6M 20.3M 20M
Intangible assets (USD) 738,000 536,000 334,000 132,000 — — — — — —
Right-of-use assets (USD) — — — 14.1M 13.1M 13M 12.5M 10.7M 8.38M 10.1M
Cash flow detail
Operating cash flow (USD) -53.5M -52.2M -31.2M -65.8M -40.7M -33.9M -25.6M -43.2M 11.4M 4.84M
Purchases of property, plant and equipment (USD) -563,000 -353,000 -1.14M -8.94M -1.62M -910,000 -2M -4.6M -2.84M -3.73M
Change in receivables (cash effect) (USD) -1.07M -5.55M 3.66M -8.13M -4.28M -4.22M -9.2M -1.1M 5.5M -396,000
Change in inventories (cash effect) (USD) -1.78M -2.09M 806,000 -6.04M -4.03M -19.6M -1.77M -14.9M 7.03M -14.7M
Change in payables (cash effect) (USD) 3.26M 2.49M 5.68M 5.02M 2.24M 12.2M -4.91M -7.34M -1.48M 5.73M
Interest paid (cash effect) (USD) -1.37M -2.03M -2.73M -3.08M -3.27M -4.18M -5.1M -9.21M -9.3M -8.52M
Income taxes paid (cash effect) (USD) -157,000 -160,000 -254,000 -229,000 -265,000 -278,000 -270,000 -322,000 -356,000 -301,000
Share-based compensation (USD) 8.07M 9.36M 10.4M 13.3M 18M 23.6M 24.5M 20.3M 22.9M 22.9M
Operating cash flow before change in receivables (USD) -52.5M -46.7M -34.9M -57.7M -36.5M -29.7M -16.4M -42.1M 5.86M 5.23M
Free cash flow (OCF - PPE - intangibles) (USD) -54.1M -52.6M -32.4M -74.8M -42.4M -34.8M -27.6M -47.8M 8.52M 1.11M
Income detail
Research and development expense (USD) 31.3M 33.7M 42.6M 60.4M 64.4M 63.7M 64.1M 67.6M 58.9M 67.7M
↳ 5y CAGR +34.3% +34.7% +22.9% +22.6% +20.2% +15.3% +13.7% +9.7% -0.5% +1.0%
Total comprehensive income (USD) -70.1M -60.8M -57.7M -70.8M -59.3M -55.2M -45.5M -36.1M -20.1M -15.4M
Comprehensive income to owners (USD) -70.1M -60.8M -57.7M -70.8M -59.3M -55.2M -45.4M -36M -20M -15.4M
Reported Mar 8, 2017 Mar 8, 2018 Feb 27, 2019 Feb 21, 2020 Feb 25, 2021 Feb 22, 2022 Mar 1, 2023 Mar 5, 2024 Feb 26, 2025 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

11/02/2026

  • Met primary efficacy endpoint demonstrating non-inferiority of INTERCEPT Red Blood Cells (RBCs) to conventional RBCs by adjusted hemoglobin increment

  • Primary safety endpoints:

  • No statistically significant difference in related treatment-emergent adverse events (TEAEs) between treatment and control arms

  • No evidence of hemolysis or clinical impact detected in treatment-emergent, low titer, transient antibodies, which were observed in RedeS, consistent with Cerus’ prior ReCePI study

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial.

“Over the past decade, pathogen reduction technology has become an integral component of the blood safety toolkit. The topline results from the RedeS study reinforce the potential to extend this established paradigm to red blood cell transfusions,” said Ross M. Fasano, MD, Professor of Pathology & Laboratory Medicine and Hematology at Emory University, and RedeS study site investigator at Grady Memorial Hospital.

RedeS Topline Results

The primary efficacy endpoint was met, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs, as measured by adjusted hemoglobin increment, a commonly used measure of RBC transfusion effectiveness1. On a modified intent to treat (mITT) basis:

  • Adjusted hemoglobin increment was 1.996 g/dL (N=195) in the INTERCEPT arm compared with 2.050 g/dL (N=199) in the control arm, for an estimated difference of -0.054 g/dL (95% CI, -0.210 to 0.103).
  • The lower bound of the 95% confidence interval was above the prespecified non-inferiority margin of −0.32 g/dL, demonstrating non-inferiority (p=0.004).

The study was designed with two prespecified primary safety endpoints.

  • The proportion of subjects with any TEAEs (possibly, probably or definitely) related to a study RBC transfusion was 3.4% (n=9) in the INTERCEPT arm (N=267) compared with 2.5% (n=7) in the control arm (N=276), with no statistically significant difference between treatment arms (p=0.634).
  • As in Cerus’ prior ReCePI study, treatment-emergent, low titer, transient INTERCEPT-specific antibodies were detected in RedeS without evidence of hemolysis or clinical impact. The proportion of subjects with INTERCEPT RBC-specific antibodies was 2.2% (n=6) in the INTERCEPT arm (N=267), compared with zero in the control arm (N=276) (p<0.013). The six INTERCEPT RBC-specific antibodies observed in the treatment arm were included in the TEAE safety endpoint.

Full study results, including secondary endpoints, are expected to be submitted to a peer-reviewed scientific journal as well as presented at upcoming scientific meetings.

“Today, we took another important step toward extending pathogen reduction to red blood cells. The topline RedeS results provide additional evidence on the performance of INTERCEPT-treated red blood cells in patients requiring transfusion support and complement the earlier results from the STARS, SPARC, and ReCePI clinical studies,” said Dr. Richard Benjamin, Cerus’ chief medical officer. “Our sincere thanks go to the patients, investigators and blood centers whose participation made this study possible.”

Cerus has ongoing studies to further evaluate the nature of INTERCEPT RBC specific antibodies observed in clinical studies.

Development of the INTERCEPT Blood System for Red Blood Cells has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Center for Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201600009C and 75A50124C00046.

The U.S. Food and Drug Administration (FDA) has not yet reviewed the final RedeS clinical study report, and its assessment of the study findings and the overall benefit-risk profile may differ from Cerus’ assessment.

The INTERCEPT Blood System for Red Blood Cells remains investigational in the United States and has not been approved by the FDA. These results do not establish regulatory approval or the timing of any potential approval.

Conference Call and Webcast

The Company will host a conference call at 4:30 P.M. ET this afternoon, during which management will discuss its third-quarter 2026 financial results, the RedeS topline results, and provide a general business overview and outlook. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.

A replay will be available on Cerus’ website approximately three hours after the call through November 23, 2026.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

1. Roubinian NH, Plimier C, Woo JP, et al. Effect of donor, component, and recipient characteristics on hemoglobin increments following red blood cell transfusion. Blood. 2019;134(13):1003-1013. doi:10.1182/blood.2019000773

Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.

Forward-Looking Statements

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: the potential of the INTERCEPT Blood System for Red Blood Cells, including Cerus potentially making pathogen reduction available for RBCs; the significance and potential implications of the topline results from the RedeS clinical trial; Cerus’ expectations regarding completion of the full analysis of the RedeS data, including secondary endpoints, and publication and presentation of the full study results; Cerus’ ongoing evaluation of INTERCEPT RBC-specific antibodies observed in clinical studies; Cerus’ plans for further clinical and regulatory activities relating to INTERCEPT RBCs; the potential timing, scope and outcome of future interactions with the FDA and other regulatory authorities; Cerus’ ability to advance the INTERCEPT Blood System for Red Blood Cells toward regulatory submissions and potential approvals in the United States, Europe and other jurisdictions; and other statements that are not historical fact.

Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the uncertain and time-consuming clinical development and regulatory review processes, including the risks that (a) Cerus may not complete a full analysis of the RedeS data or publish and present the full study results in a timely manner or at all, (b) the topline RedeS results reported herein and related findings and conclusions may change following completion of the full analysis of the study data, including secondary endpoints, (c) the full RedeS results may differ from or not support the conclusions suggested by the topline results, (d) additional analyses, clinical studies or other data may be required to support regulatory submissions or approvals for INTERCEPT RBCs, (e) Cerus and the FDA or other regulatory authorities may reach different conclusions regarding the RedeS results, INTERCEPT RBC-specific antibodies, the overall benefit-risk profile of INTERCEPT RBCs or the clinical or regulatory requirements necessary to support approval, (f) Cerus may be unable to complete planned clinical, regulatory or development activities in a timely manner or at all, (g) any regulatory submission for INTERCEPT RBCs may be delayed, may not be accepted for review, or may not be approved in a timely manner or at all, and (h) Cerus may be unable to obtain or maintain regulatory approvals for INTERCEPT RBCs in the United States, Europe or other jurisdictions; risks related to product safety and efficacy, including the occurrence, persistence or potential clinical significance of antibody reactivity to INTERCEPT RBCs; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction is safe, effective and economical; risks associated with Cerus’ ability to maintain an effective and secure manufacturing and supply chain and comply with applicable regulatory requirements; risks associated with macroeconomic, geopolitical and financial market developments; Cerus’ need for additional funding; and other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Cerus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and Cerus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

Tim Lee – Head of Investor Relations
Cerus Corporation
[email protected]
925-288-6128

Source: Cerus Corporation

View All News

Cerus Corporation Logo Footer

Global Headquarters

1220 Concord Avenue

Concord, CA US 94520

+1 925.288.6000

European Headquarters

Stationsstraat 79-D

3811 MH Amersfoort, Netherlands

+31 (0) 33 49 60 600

Copyright (c) 2026 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc.

Back to top

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn .

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

About Cerus

11/02/2026

Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y

Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red blood cells (RBCs)

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update.

"Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end,” said Vivek Jayaraman, Cerus’s president and chief executive officer. “Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care. The positive topline results we announced today from the Phase 3 RedeS study mark an important milestone as we drive toward extending the benefits of pathogen reduction to red cell transfusions. I’m pleased with our progress and grateful to my colleagues who remain focused on delivering for our customers and the patients they serve.”

  • Achieved third-quarter 2026 product revenue of $57.7 million representing 10% growth compared to the prior year period.
Three Months Ended Nine Months Ended
September 30, Change September 30, Change
2026 2025 $ % 2026 2025 $ %
Product Revenue $ 57.7 $ 52.7 $ 5.0 10 % $ 168.8 $ 148.4 $ 20.4 14 %
Government Contract Revenue 6.3 7.5 (1.2 ) -16 % 18.4 20.8 (2.4 ) -12 %
Total Revenue $ 64.0 $ 60.2 $ 3.8 6 % $ 187.2 $ 169.2 $ 18.0 11 %
Numbers may not sum due to rounding. Percentages calculated from unrounded figures.
  • Drove approximately 80% growth in INTERCEPT Fibrinogen Complex (IFC) volumes – including kits and finished therapeutic doses (measured in FC15* equivalent units) compared to the prior year period. Third quarter U.S. IFC sales totaled $5.6 million, up from $3.9 million in the prior year period.
  • Announced positive topline results from the Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells.
  • Appointed Betsy Jensen as chief human resources officer, fully effective December 2026. Ms. Jensen joins Cerus from Standard BioTools, where she has served as senior vice president and chief human resources officer.
  • Generated operating cash flow of $3.0 million in the third quarter of 2026. Increased cash, cash equivalents, and short-term investments by $0.8 million compared to June 30, 2026 to $57.1 million at September 30, 2026.

Revenue

Product revenue for the third quarter of 2026 was $57.7 million, compared to $52.7 million for the prior year period, representing year-over-year growth of 10%. Third quarter growth was driven by higher U.S. IFC sales, strength of the U.S. platelet franchise, and INT200 illuminator sales in EMEA.

Government contract revenue for the third quarter of 2026 was $6.3 million, compared to $7.5 million during the prior year period. The decrease reflects the completion of the Company’s FDA contract in 2025 and the wind-down of the Biomedical Advanced Research and Development Authority (BARDA) 2016 contract which was offset in part by an increase in expenses related to the BARDA 2024 contract.

Product Gross Profit & Margin

Product gross profit for the third quarter of 2026 was $30.3 million, compared to $28.1 million, increasing by 8% over the prior year period. Product gross margin for the third quarter was 52.4% compared to 53.4% in the same period last year. The year-over-year decrease in gross margin was largely driven by a weaker U.S. dollar relative to the euro and higher product costs driven by inflationary pressures offset partially by pricing and favorable product mix shift.

Operating Expenses

Total operating expenses for the third quarter of 2026 were $36.2 million, compared to $34.4 million for the same period of the prior year, reflecting a year-over-year increase of 5%.

R&D expenses for the third quarter of 2026 were $14.3 million, compared to $15.8 million in the third quarter of 2025. The decrease primarily reflected lower costs associated with the RedeS study following completion of enrollment, INT200 development following the U.S. PMA submission, and expenses tied to government-funded projects, as reflected in government contract revenue.

SG&A expenses totaled $21.9 million for the third quarter of 2026, compared to $18.6 million for the third quarter of 2025. The year-over-year increase in SG&A expenses was due in part to higher employee-related expenses. In addition, SG&A expenses for Q3 2025 benefited from a one-time tax credit.

Net Loss Attributable to Cerus Corporation

Net loss attributable to Cerus Corporation for the third quarter of 2026 was $0.6 million, or $0.00 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $0.02 million, or $0.00 per basic and diluted share, for the same period of the prior year. Net loss attributable to Cerus Corporation for the first nine months of 2026 was $5.1 million, compared to net loss attributable to Cerus Corporation of $13.4 million for the first nine months of 2025.

Non-GAAP Adjusted EBITDA

Non-GAAP adjusted EBITDA for the third quarter of 2026 was positive $5.7 million, compared to non-GAAP adjusted EBITDA of positive $5.0 million for the same period of the prior year. Non-GAAP adjusted EBITDA for the first nine months of 2026 was a positive $12.7 million compared to non-GAAP adjusted EBITDA of positive $6.1 million for the first nine months of 2025.

Balance Sheet and Cash Flows

At September 30, 2026, the Company had cash, cash equivalents, and short-term investments of $57.1 million, compared to $82.9 million at December 31, 2025 and $56.3 million at June 30, 2026.

As of September 30, 2026, the Company had $35.0 million outstanding on its term loan and $28.5 million drawn on its revolving credit facility, down from $30.1 million drawn at June 30, 2026. Subject to borrowing base levels, the Company’s revolving line of credit allows for an additional $16.5 million as of September 30, 2026.

For the third quarter of 2026, cash generated from operations totaled $3.0 million, compared to $1.9 million generated during the same period of the prior year. Cash generated from operations in the third quarter of 2026 was driven by sequentially improved bottom-line results and inventory management.

Reiterating Full-Year 2026 Product Revenue Guidance

The Company continues to expect full-year 2026 product revenue to be in the range of $229 million to $231 million, reflecting growth of 11% to 12% from 2025. Included in this range is full-year 2026 IFC revenue guidance of $23 million to $25 million.

Quarterly Conference Call

The Company will host a conference call at 4:30 P.M. ET this afternoon, during which management will discuss the Company’s financial results, topline results from the Phase 3 RedeS study, and provide a general business overview and outlook. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.

A replay will be available on Cerus’ website approximately three hours after the call through November 23, 2026.

*FC15 equivalent to a therapeutic dose of a cryoAHF pool.

Development of the INTERCEPT Blood System for Red Blood Cells has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Center for Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201600009C and 75A50124C00046.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.

Forward-Looking Statements

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: Cerus’ expectation that full-year 2026 product revenue will be in the range of $229 million to $231 million, including IFC revenue of between $23 million to $25 million; Cerus’ expectation that full-year 2026 product revenue will grow 11% to 12% year over year; Cerus continuing to have access to $16.5 million under its revolving line of credit; Cerus’ expectations with respect to the FDA’s review of the U.S. PMA submission for Cerus’ new INT200 illumination device; the significance and potential implications of the topline results from the RedeS clinical trial; Cerus’ plans for further clinical and regulatory activities relating to INTERCEPT RBCs; the potential timing, scope and outcome of future interactions related to INTERCEPT RBCs with the FDA and other regulatory authorities; Cerus’ ability to advance the INTERCEPT Blood System for RBCs toward regulatory submissions and potential approvals in the United States, Europe and other jurisdictions; Cerus’ expectations with respect to its collaboration with Blood Centers of America; Cerus’ ability to continue to improve global access to its INTERCEPT technologies, Cerus’ anticipated growth trajectory, and potential market opportunities; Cerus’ ability to advance its product development programs; the continued commercialization and launch of INT200 and IFC; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System and IFC; the risk that Cerus may not meet its 2026 annual product revenue guidance; the risk that Cerus may not effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation or INT200; the risk that Cerus may not grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contributions resulting from its U.S. and European market agreements; the risk that the topline RedeS results reported herein and related findings and conclusions may change following completion of the full analysis of the study data, including secondary endpoints; risks related to the uncertain and time-consuming development and regulatory process, including the risk that Cerus may be unable to obtain requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all, including the risks that existing clinical data may be insufficient in order to obtain a CE Certificate of Conformity and affix a CE Mark to the red blood cell system and its planned modular premarket approval, or PMA, application for the red blood cell system may not be submitted to the FDA on the timeline Cerus anticipates or at all and/or the regulatory decision with respect to Cerus’ modular PMA application for the INT200 may not occur on the timeline Cerus anticipates or at all; risks associated with macroeconomic developments, including the ongoing military conflict in Ukraine and the ongoing military conflict involving Iran, the U.S. and Israel, new or increased tariffs and escalating trade tensions, inflation, rising interest rates and foreign exchange volatility and the resulting global economic and financial disruptions; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other healthcare constituencies that pathogen reduction and the INTERCEPT Blood System are safe, effective and economical; risks related to product safety; risks associated with Cerus’ ability to maintain an effective, secure manufacturing supply chain, including risks that (a) Cerus’ supply chain could be negatively impacted as a result of macroeconomic developments, (b) Cerus’ manufacturers could be unable to comply with extensive regulatory agency requirements, and (c) Cerus may be unable to maintain its supply agreements with its third-party suppliers; risks associated with Cerus’ ability to access additional funds under its credit facility and to meet its debt service obligations, and its need for additional funding; risks associated with the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Cerus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

Use of Non-GAAP Financial Measures

We define adjusted EBITDA as net loss attributable to Cerus Corporation as reported on the consolidated statement of operations, as adjusted to exclude, as applicable for the reporting period(s) presented, (i) net loss attributable to noncontrolling interest, (ii) provision for income taxes, (iii) foreign exchange (loss)/gain, (iv) interest income (expense), (v) other income (expense), net, (vi) depreciation and amortization, (vii) share-based compensation, (viii) goodwill and asset impairments, (ix) costs associated with our noncontrolling interest in our joint venture in China and, (x) revenue and direct costs associated with our government contracts. We are presenting this non-GAAP financial measure to assist investors in assessing our operating results. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Cerus’ GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Cerus’ operating results as reported under GAAP. This non-GAAP financial measure should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. This non-GAAP financial measure is not necessarily comparable to similarly-titled measures presented by other companies.

Supplemental Tables

Three Months Ended Nine Months Ended
September 30, September 30,
2026 vs. 2025 2026 vs. 2025
Platelet Kit Growth
North America 5% 4%
International -3% 5%
Worldwide 3% 4%
Change in Calculated Number of Treatable Platelet Doses
North America 5% 6%
International -4% 3%
Worldwide 2% 5%
Dose treatable calculation based on the number of kits sold and the product configuration (single and double dose kits)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 vs. 2025 2026 vs. 2025
Total IFC* Demand Growth ~80% ~60%
(including kits and finished therapeutic doses)
*FC15 equivalent to a therapeutic dose of a cryoAHF pool.
CERUS CORPORATION
REVENUE BY REGION
(in thousands, except percentages)
Three Months Ended Nine Months Ended
September 30, Change September 30, Change
2026 2025 $ % 2026 2025 $ %
North America $ 39,136 $ 35,031 $ 4,105 12 % $ 114,247 $ 100,916 $ 13,331 13 %
Europe, Middle East and Africa 17,645 16,744 901 5 % 51,659 45,569 6,090 13 %
Other 933 923 10 1 % 2,910 1,897 1,013 53 %
Total product revenue $ 57,714 $ 52,698 $ 5,016 10 % $ 168,816 $ 148,382 $ 20,434 14 %
CERUS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(in thousands, except per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
Product revenue $ 57,714 $ 52,698 $ 168,816 $ 148,382
Cost of product revenue 27,449 24,558 81,125 65,843
Gross profit on product revenue 30,265 28,140 87,691 82,539
Government contract revenue 6,304 7,539 18,398 20,837
Operating expenses:
Research and development 14,268 15,825 43,188 51,330
Selling, general and administrative 21,918 18,618 64,730 60,086
Total operating expenses 36,186 34,443 107,918 111,416
Income (loss) from operations 383 1,236 (1,829 ) (8,040 )
Total non-operating expense, net (897 ) (1,171 ) (3,129 ) (5,178 )
(Loss) income before income taxes (514 ) 65 (4,958 ) (13,218 )
Provision for income tax 66 85 252 235
Net loss (580 ) (20 ) (5,210 ) (13,453 )
Net loss attributable to noncontrolling interest (30 ) (1 ) (80 ) (10 )
Net loss attributable to Cerus Corporation $ (550 ) $ (19 ) $ (5,130 ) $ (13,443 )
Net loss per share attributable to Cerus Corporation
Basic and diluted $ (0.00 ) $ (0.00 ) $ (0.03 ) $ (0.07 )
Weighted average shares outstanding:
Basic and diluted 201,653 191,830 198,814 190,083
CERUS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 30, December 31,
2026 2025
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 16,350 $ 19,961
Short-term investments 40,759 62,918
Accounts receivable, net 30,560 30,374
Current inventories 64,689 56,101
Prepaid and other current assets 4,212 5,030
Total current assets 156,570 174,384
Non-current assets:
Property and equipment, net 9,423 9,204
Operating lease right-of-use assets 8,797 10,124
Goodwill 1,316 1,316
Non-current inventories 15,635 15,143
Other assets and restricted cash 12,988 11,688
Total assets $ 204,729 $ 221,859
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 46,758 $ 53,279
Debt – current 28,504 43,343
Operating lease liabilities – current 3,311 2,905
Deferred revenue – current 1,433 1,274
Total current liabilities 80,006 100,801
Non-current liabilities:
Debt – non-current 34,846 40,545
Operating lease liabilities – non-current 8,299 10,153
Other non-current liabilities 5,216 5,395
Total liabilities 128,367 156,894
Stockholders' equity: 75,701 64,224
Noncontrolling interest 661 741
Total liabilities and stockholders' equity $ 204,729 $ 221,859
CERUS CORPORATION
UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA
(in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
Net loss attributable to Cerus Corporation $ (550 ) $ (19 ) $ (5,130 ) $ (13,443 )
Adjustments to net loss attributable to Cerus Corporation:
Net loss attributable to noncontrolling interest (30 ) (1 ) (80 ) (10 )
Provision for income taxes 66 85 252 235
Total non-operating expense, net (i) 897 1,171 3,129 5,178
Income (loss) from operations 383 1,236 (1,829 ) (8,040 )
Adjustments to income (loss) from operations:
Operating depreciation and amortization 1,126 1,068 3,565 3,132
Government contract revenue (ii) (6,304 ) (7,539 ) (18,398 ) (20,837 )
Direct expenses attributable to government contracts(iii) 4,363 4,640 12,736 13,908
Share-based compensation (iv) 6,097 5,624 16,497 17,940
Costs attributable to noncontrolling interest(v) 62 3 164 21
Non-GAAP adjusted EBITDA $ 5,727 $ 5,032 $ 12,735 $ 6,124
i. Includes interest income/expense and foreign exchange gains/losses.
ii. Represents revenue related to the cost reimbursement provisions under our government contracts.
iii. Represents the direct expenses attributable to work supporting government contracts, which are reimbursed and reflect under government contract revenue in the condensed consolidated statement of operations.
iv. Represents non-cash stock-based compensation.
v. Represents costs associated with the noncontrolling interest in Cerus Zhongbaokang (Shandong) Biomedical Co., LTD.

Tim Lee – Head of Investor Relations
Cerus Corporation
[email protected]
925-288-6128

Source: Cerus Corporation

View All News

Cerus Corporation Logo Footer

Global Headquarters

1220 Concord Avenue

Concord, CA US 94520

+1 925.288.6000

European Headquarters

Stationsstraat 79-D

3811 MH Amersfoort, Netherlands

+31 (0) 33 49 60 600

Copyright (c) 2026 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc.

Back to top

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn .

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

About Cerus

10/19/2026

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here

. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website approximately three hours after the call through November 23, 2026.

Prompts

Cerus Corporation (ticker CERS), listed in United States.

ETFs Holding Cerus Corporation

ETF Weight in ETF Shares Market value As of
ARKG 0.87% 8,308,352 $ 15.786M Nov 18, 2026
ARKK 0.25% 16,872,255 $ 32.057M Nov 18, 2026
OASC 0.23% 82,370 $ 217.457K Aug 31, 2026
FSML 0.11% 47,888 $ 139.833K Jun 30, 2026
FESM 0.06% 1,208,271 $ 3.528M Jun 30, 2026
VFMO 0.06% 421,234 $ 1.112M Aug 31, 2026
FEAC 0.04% 3,607 $ 10.532K Jun 30, 2026
RESM 0.03% 331 $ 966.52 Jun 30, 2026
DFSU 0.00% 19,324 $ 37.489K Nov 12, 2026
DFAS 0.00% 31,084 $ 60.303K Nov 12, 2026
DCOR 0.00% 31,450 $ 61.013K Nov 12, 2026
DFUS 0.00% 14,390 $ 27.917K Nov 12, 2026